|

Tiragolumab Clinical Trials

6 actively recruiting trials across 3 locations

▼ -2 trials since August 2026

Also known as: Anti-TIGIT, MTIG7192A, RG-6058, RO7092284, anti-TIGIT

Pipeline

Phase 1: 1Phase 2: 2Phase 3: 1Phase 1/2: 2

Top Sponsors

  • Hoffmann-La Roche2
  • The Netherlands Cancer Institute1
  • Omico1
  • M.D. Anderson Cancer Center1
  • Alliance Foundation Trials, LLC.1

Indications

  • Cancer6
  • Metastatic Malignancy1
  • Metastatic Breast Cancer1
  • Endometrial Cancer1
  • Solid Tumor, Adult1

Other3 trials

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Phase 3
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
Phase 2
Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients
Phase 2

Birmingham, Alabama1 trial

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

UAB Comprehensive Cancer Center

Phase 1

Duarte, California1 trial

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

City of Hope Comprehensive Cancer Center

Phase 1/2

Houston, Texas1 trial

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

M D Anderson Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.